An Irvine drug maker, Spectrum Pharmaceuticals Inc., has said that it got regulatory approval for an expanded use of a cancer drug.
Spectrum said that the FDA approved Zevalin as an early treatment for a blood cancer, in patients with non-Hodgkin's lymphoma. The drug was used previously on patients whose tumors did not respond to other treatments.
Spectrum Pharmaceuticals and Cell Therapeutics have entered into an agreement to form a 50:50 owned joint venture, RIT Oncology, to commercialize and develop Zevalin in the United States.
- Pebble launches its App Store on Android smartphones
- Oscar Mayer unveils new ‘Wake Up & Smell the Bacon’ alarm-clock app for iPhone
- Dyson launches a quieter, more efficient bladeless fan
- Samsung reveals new Black Edition models of Galaxy S4 and S4 Mini
- Panasonic announces Lumix DMC-GH4 camera with built-in 4K video recording